SUZHOU FUSHILAI PHARMACEUTICAL CO., LTD.

Suzhou Fushilai Pharmaceutical Co., Ltd.

301258

CNE1000058W2

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 18:00:00 2024-05-16 EDT			5-day change	1st Jan Change
35.6 ^CNY	+1.48%		-0.22%	+10.29%

04-22	Suzhou Fushilai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-01	Tranche Update on Suzhou Fushilai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 6, 2024.	CI

Suzhou Fushilai Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2022

April 18, 2023 at 03:40 pm

Suzhou Fushilai Pharmaceutical Co., Ltd. proposed final cash dividend (tax included) of CNY 5.80000000 per ten shares for the year 2022.

Latest news about Suzhou Fushilai Pharmaceutical Co., Ltd.

Suzhou Fushilai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-22	CI
Tranche Update on Suzhou Fushilai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 6, 2024.	04-01	CI
Certain A Shares of Suzhou Fushilai Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 29-MAR-2024.	03-28	CI
Suzhou Fushilai Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 40 million worth of its shares.	02-06	CI
Suzhou Fushilai Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	02-04	CI
Fushilai Pharmaceutical Co., Ltd. announced that it expects to receive CNY 200 million in funding from Suzhou Fushilai Pharmaceutical Co., Ltd.	12-17	CI
Suzhou Fushilai Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-19	CI
Suzhou Fushilai Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-21	CI
Suzhou Fushilai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-17	CI
Suzhou Fushilai Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17	CI
Certain A Shares of Suzhou Fushilai Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 29-MAR-2023.	23-03-28	CI
Fushilai Pharmaceutical to Apply for 375 Million Yuan Credit Lines This Year	23-03-16	MT
Suzhou Fushilai Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-25	CI
Suzhou Fushilai Pharmaceutical Co., Ltd. Approves Management Appointments	22-09-13	CI
Suzhou Fushilai Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-22	CI
Suzhou Fushilai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-26	CI
Suzhou Fushilai Pharmaceutical Co., Ltd. has completed an IPO in the amount of CNY 1.107036 billion.	22-03-23	CI
Suzhou Fushilai Pharmaceutical Co., Ltd. has filed an IPO.	21-08-16	CI
Suzhou Fushilai Pharmaceutical Co., Ltd. has withdrawn its IPO.	21-08-15	CI
Suzhou Fushilai Pharmaceutical Co., Ltd. has filed an IPO.	21-06-22	CI

Chart Suzhou Fushilai Pharmaceutical Co., Ltd.

Duration

Period

Chart Suzhou Fushilai Pharmaceutical Co., Ltd.

More charts

Suzhou Fushilai Pharmaceutical Co Ltd is a China-based company mainly engaged in the production and sales of pharmaceuticals. The Company is mainly engaged in the research and development, production and sales of pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and raw materials for health care products. The Company's main products include three series of lipoic acid series, phosphatidylcholine series and carnosine series. The Company mainly conducts its business in domestic and overseas markets such as Europe, America, Japan and South Korea, India and South America.

Sector

Pharmaceuticals

Calendar

2024-08-19 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SUZHOU FUSHILAI PHARMACEUTICAL CO., LTD.	+10.29%	452M
ELI LILLY AND COMPANY	+32.09%	693B
NOVO NORDISK A/S	+29.39%	584B
JOHNSON & JOHNSON	-1.34%	372B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+7.39%	294B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	211B
NOVARTIS AG	+10.02%	210B
AMGEN INC.	+8.49%	168B

Other Pharmaceuticals